Affiliations: [a] Department of Paediatrics, Queen’s University, Kingston, ON, Canada
| [b] Department of Paediatrics, Division of Neonatology, University of Toronto, Toronto, ON, Canada
| [c] Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Address for correspondence: Michael Dunn, MD, Department of Newborn and Developmental Paediatrics, Aubrey and Marla Dan Program for High Risk Mothers and Infants, Sunnybrook Health Sciences Centre, Room M4-222, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. Tel.: +1416 480 6100; Ext. 87777; Fax: +1416 480 5612; E-mail: email@example.com.
Abstract: OBJECTIVES: A new guideline for the early respiratory management of preterm infants that included early nCPAP and INSURE was recently introduced in our NICU. This case series describes the clinical courses of a group of preterm infants managed according to this guideline, and reports the rates of successful extubation within 30 minutes of surfactant administration with and without the use of naloxone and adverse events encountered. STUDY DESIGN: Descriptive case series of all preterm babies admitted to our unit who were candidates for INSURE procedure with premedication from August 2012 to August 2013. RESULTS: A total of 31 infants were included with a mean birth weight of 1178 grams and a mean gestational age of 28.4 weeks. Twelve out of thirteen (92%) infants in the naloxone group were extubated within 30 minutes of surfactant administration while only 12/18 (67%) in the non-naloxone group were extubated within the same time frame. No adverse reactions were noted with naloxone usage in this context. CONCLUSION: Naloxone can be effective in reversing the respiratory depressive effect of analgesic premedication and in turn facilitates expeditious extubation in some preterm infants intubated for INSURE procedure.